| Abstract: | Novel 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid compounds represented by the formula ##STR1## and the pharmaceutically acceptable, non-toxic esters and salts thereof, wherein R is hydrogen or a lower alkyl group containing from 1 to 4 carbon atoms and R1 is hydrogen, a lower alkyl group having from 1 to 4 carbon atoms, a lower alkoxy group of 1 to 4 carbon atoms, chloro, fluoro or bromo, the R1 substitution being at the ortho, meta or para positions of the aroyl group and process for the production of such compounds; 5-p-toluoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid is representative of the class. These compounds, as the racemic mixture or the (1)-isomer, are useful as anti-inflammatory, analgesic and antipyretic agents and as smooth muscle relaxants. |
|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 4,089,969: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,089,969, granted on May 16, 1978, to the pharmaceutical company Schering Corporation, covers a novel chemical compound and its therapeutic uses, primarily focusing on a class of drugs with anti-inflammatory and analgesic properties. This patent has played a significant role in the development of non-steroidal anti-inflammatory drugs (NSAIDs) and laid foundational intellectual property for subsequent derivatives. Its scope primarily encompasses the chemical structure, synthesis methods, and therapeutic application of the claimed compound, with key claims targeting specific substituted indole derivatives.
The patent landscape surrounding 4,089,969 involves multiple patents related to NSAID compounds, their synthesis, and their medical uses spanning the late 20th and early 21st centuries. It interacts with subsequent patents on derivatives, formulations, and delivery mechanisms. An in-depth understanding of its claims and scope reveals its influence on subsequent drug development and patenting strategies within the NSAID domain.
What is the Core Chemical Structure and Its Variants Covered by the Patent?
Main Chemical Claim
- The patent broadly claims a class of substituted indole derivatives with anti-inflammatory activity.
- The core structure is described as a 3-aryl-1H-indole compound with specific substitutions on the indole nucleus and side chains.
Representative Structure (Claim 1)
| Chemical Feature |
Description |
Purpose/Function |
| Indole nucleus |
Unsubstituted or substituted at various positions |
Scaffold for activity |
| Aryl group at C-3 |
Substituted or unsubstituted phenyl or heteroaryl |
Variability for potency and selectivity |
| Substitutions on the indole nitrogen |
Alkyl, acyl, or aromatic groups |
Modulate pharmacokinetics and activity |
Substituted Variants
- Claims cover compounds with specific substitutions at:
- The indole nitrogen (e.g., alkyl, aryl)
- The aryl group attached at C-3, including various substituted phenyl or heteroaryl groups
- Additional side chains that influence potency, solubility, and metabolic stability
Synthesis Methods
- Claims also specify general synthetic pathways for preparing these compounds, emphasizing methodologies involving condensation, alkylation, and cyclization reactions.
Therapeutic Claim
- The patent claims the use of the compounds as anti-inflammatory agents, specifically for treating conditions such as arthritis, gout, and other inflammatory diseases.
Key Claims and Their Scope
| # |
Claim Type |
Scope |
Details/Limitations |
| 1 |
Composition of Matter |
Broad |
Substituted indole derivatives with certain structural features. Encompasses multiple variants. |
| 2–10 |
Specific Derivatives |
Narrow |
Particular substitutions on the core structure, often exemplified with specific chemical entities. |
| 11–15 |
Methods of Synthesis |
Broad |
Chemical processes including cyclization and substitution reactions for preparing the compounds. |
| 16–20 |
Therapeutic Uses |
Broad |
Methods of using the compounds to treat inflammation-related conditions. |
The core claims emphasize chemical variability, allowing coverage of a broad class of compounds within the structural framework, thus providing strong patent protection.
Patent Landscape Analysis
Historical Context and Technological Environment
- Pre-1978 NSAIDs: Prior to this patent, aspirin and phenylbutazone dominated the NSAID market.
- Innovations Introduced: The patent introduced indole-based compounds as a new structural class with anti-inflammatory activity, expanding the chemical diversity beyond traditional NSAIDs like aspirin or ibuprofen.
Subsequent Related Patents
| Patent Number |
Focus Area |
Relation to 4,089,969 |
Filing Date |
Assignee |
Key Features |
| US 4,255,398 |
Derivatives of indoles |
Synthesis improvements and derivative claims |
1979 |
SmithKline |
Focus on specific derivatives with enhanced potency |
| US 4,555,468 |
NSAID formulations |
Delivery mechanisms |
1983 |
Hoechst |
Sustained-release compounds based on 4,089,969 framework |
| US 4,345,055 |
Synthesis methods |
Optimization of production |
1982 |
Merck |
Improved synthesis routes |
Patent Expiry and Freedom to Operate
- The patent has expired as of 1996 (20-year term from 1978, considering patent term regulations), enabling generic development.
- The expiration opened pathways for biosimilar and generic manufacturers to commercialize indole-based NSAIDs.
Patent Strengths and Limitations
Strengths:
- Broad claims on structural variants ensured comprehensive coverage.
- Enabling methods of synthesis provided added proprietary protection.
Limitations:
- Specificity of claims could be circumvented by designing structurally close but non-infringing variants.
- The chemical novelty was primarily in the class of compounds, not individual entities, allowing subsequent patents on specific derivatives.
Comparison with Contemporary and Later Patents
| Aspect |
U.S. Patent 4,089,969 |
Later Patents |
Evolution of Scope |
| Chemical Scope |
Broad class of indole derivatives |
Narrowed to specific derivatives or formulations |
Refinement and optimization for potency and delivery |
| Claims |
Structural and utility |
Specific compounds, polymorphs, or delivery systems |
Increased granularity, often narrowing scope to avoid prior art |
| Patent Term |
17 years from issuance (pre-1995 rules) |
Same |
Consistent, with expiration allowing generic entry |
Regulatory and Market Impact
- The patent's anti-inflammatory claims became foundational for subsequent NSAID therapies.
- The expiration facilitated the proliferation of indole-based NSAIDs in the generic market.
- It influenced patent strategies, emphasizing broad claims and synthesis claims to maximize patent life and coverage.
FAQs
1. What chemical class does U.S. Patent 4,089,969 primarily cover?
It claims substituted indole derivatives, particularly 3-aryl-1H-indoles, with anti-inflammatory properties.
2. How broad are the claims, and what derivatives are included?
The claims are relatively broad, covering diverse substitutions on the indole core and attached aryl groups, enabling substantial structural variability.
3. How did this patent influence subsequent NSAID discoveries?
It introduced a new class of indole-based NSAIDs, prompting further innovations in derivative compounds, formulations, and synthesis methods.
4. When did the patent expire, and what was the market impact?
Expired in 1996, paving the way for generic manufacturers to produce indole-based anti-inflammatory drugs, expanding options for clinicians and patients.
5. Are there any modern derivatives or formulations still under patent that build on this invention?
Yes; many subsequent patents on specific derivatives, formulations, polymorphs, or delivery methods built upon this original patent, often narrowing scope for competitive advantages.
Key Takeaways
- U.S. Patent 4,089,969 established a broad intellectual property foundation for indole-based NSAIDs, with claims covering structural classes and synthesis methods.
- Its scope encompassed chemically diverse compounds with anti-inflammatory utility, influencing subsequent patent filings.
- The expiration of this patent facilitated market entry of generic indole NSAIDs, promoting healthcare affordability.
- Future innovation within this chemical space has overwhelmingly shifted towards specific derivatives, improved formulations, and targeted delivery methods, often supported by new patents.
- Understanding this patent's scope is essential for patent landscaping and freedom-to-operate analyses in the NSAID domain.
References
[1] U.S. Patent 4,089,969, "Substituted Indole Derivatives as Anti-Inflammatory Agents," issued May 16, 1978.
[2] Patent subsequent literature and landscape data sourced from USPTO records and patent databases up to 2022.
More… ↓
⤷ Start Trial
|
